株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

疼痛管理薬の世界市場:2016〜2020年

Global Pain Management Drugs Market 2016-2020

発行 TechNavio (Infiniti Research Ltd.) 商品コード 298326
出版日 ページ情報 英文 94 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
疼痛管理薬の世界市場:2016〜2020年 Global Pain Management Drugs Market 2016-2020
出版日: 2016年08月01日 ページ情報: 英文 94 Pages
概要

世界の疼痛管理薬市場は、2016年から2020年にかけて、4.97%の複合年間成長率(CAGR)で拡大する見込みです。この成長の背景には、世界的な人口の高齢化があります。しかし、ジェネリック医薬品の台頭が、この市場の成長を阻害する要因になるかも知れません。

当レポートでは、世界における疼痛管理薬市場の現状と将来の見通し、疼痛の種類/地域別の動向、市場の成長因子と課題、主要ベンダーの分析などを提供しております。

第1章 エグゼクティブサマリー

第2章 調査範囲

  • 市場概要
  • 主な製品

第3章 市場調査手法

  • 調査手法
  • 経済指標

第4章 イントロダクション

  • 市場の主な見どころ
  • 疼痛管理の評価
  • 治療

第5章 パイプラインポートフォリオ

  • パイプライン候補情報

第6章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第7章 薬物クラス別市場区分

  • オピオイド
  • NSAID(非ステロイド系抗炎症薬)
  • その他
  • オピオイドの世界市場
  • NSAIDの世界市場

第8章 種類別の市場区分

  • 筋骨格系疼痛
  • 術後/外傷性疼痛
  • 癌性疼痛
  • 熱疼痛
  • 偏頭痛
  • 産科疼痛
  • 線維筋痛
  • 灼熱痛
  • 歯科/顔面疼痛
  • 小児疼痛
  • 神経因性疼痛
  • 筋骨格系疼痛薬の世界市場
  • 術後/外傷性疼痛薬の世界市場
  • 癌性疼痛薬の世界市場
  • 熱疼痛薬の世界市場
  • 偏頭痛薬の世界市場
  • 産科疼痛薬の世界市場
  • 線維筋痛薬の世界市場
  • 灼熱痛薬の世界市場
  • 歯科/顔面疼痛薬の世界市場
  • 小児疼痛薬の世界市場
  • 神経因性疼痛薬の世界市場

第9章 地理区分

  • 南北アメリカの疼痛管理薬市場
  • EMEA地域の疼痛管理薬市場
  • アジア太平洋地域の疼痛管理薬市場

第10章 市場成長因子

第11章 成長因子とその影響

第12章 市場の課題

第13章 成長因子と課題の影響

第14章 市場動向

第15章 ベンダー情勢

  • 競合シナリオ
  • AstraZeneca
  • Endo International
  • Johnson & Johnson
  • Pfizer
  • Purdue Pharma
  • その他の有力ベンダー
  • 略語一覧

第16章 Technavioについて

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR8628

About Pain

Pain is defined as a complex medical problem that can have profound effects not only on one's physical but also mental well-being. Pain management is a branch of medicine, which employs approach for easing the suffering and improving the quality of life of individuals suffering from pain. It can be simple or complex type, depending on the cause of pain. Pain management comprises of a variety of skills and techniques used for the treatment of pain.

Technavio's analysts forecast the global pain management drugs market to grow at a CAGR of 4.97% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global pain management drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs that are used for the management of pain.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Pain Management Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AstraZeneca
  • Endo International
  • Johnson & Johnson
  • Pfizer
  • Purdue Pharma

Other Prominent Vendors

  • Allergan
  • AstraZeneca
  • Baxter
  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Durect
  • GlaxoSmithKline
  • Hospira
  • Merck
  • Novartis
  • Pain Therapeutics
  • F. Hoffmann-La Roche
  • Sanofi
  • UCB
  • Valeant
  • Taro Pharmaceuticals
  • Achelios Therapeutics
  • Alder Biopharmace-uticals
  • Amgen
  • CoLucid
  • Daiichi Sankyo
  • Dr. Reddy's Laboratories
  • Eli Lilly
  • GW Pharmaceuticals
  • Immune Pharmaceuticals
  • Innovative Med Concepts
  • NeurAxon
  • OptiNose
  • RedHill
  • Sorrento Therapeutics
  • SUDA
  • Teva
  • Tonix
  • Trigemina
  • WEX Pharmaceuticals
  • Zynerba Pharmaceuticals

Market driver

  • Increase in awareness of pain management drugs
  • For a full, detailed list, view our report

Market challenge

  • Preference for alternative therapies
  • For a full, detailed list, view our report

Market trend

  • Off-label drug usage
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Assessment of pain
  • Treatment

PART 05: Pipeline portfolio

  • Information on pipeline candidates

PART 06: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 07: Market segmentation by drug class

  • Opioids
  • NSAIDs
  • Other
  • Global opioids market
  • Global NSAIDs market

PART 08: Market segmentation by type

  • Musculoskeletal pain
  • Surgical and trauma pain
  • Cancer pain
  • Neuropathic pain
  • Migraine pain
  • Obstetrical pain
  • Fibromyalgia pain
  • Burn pain
  • Dental/facial pain
  • Pediatric pain
  • Global musculoskeletal pain drugs market
  • Global surgical and trauma pain drugs market
  • Global cancer pain drugs market
  • Global neuropathic pain drugs market
  • Global migraine pain drugs market
  • Global obstetrical pain drugs market
  • Global fibromyalgia pain drugs market
  • Global burn pain drugs market
  • Global dental/facial pain drugs market
  • Global pediatric pain drugs market

PART 09: Geographical segmentation

  • Pain management drugs market in Americas
  • Pain management drugs market in EMEA
  • Pain management drugs market in APAC

PART 10: Market drivers

  • Rise in older population
  • Promising pipeline
  • Increase in awareness of pain management drugs
  • Favorable regulatory scenario

PART 11: Impact of drivers

PART 12: Market challenges

  • Generic competition
  • Adverse effects
  • Preference for alternative therapies
  • Short-term relief
  • Threat of counterfeit products

PART 13: Impact of drivers and challenges

PART 14: Market trends

  • Increase in R&D activities
  • Off-label drug usage
  • Strategic alliances

PART 15: Vendor landscape

  • Competitive scenario
  • AstraZeneca
  • Endo International
  • Johnson & Johnson
  • Pfizer
  • Purdue Pharma
  • Other prominent vendors
  • List of abbreviations

PART 16: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Pain assessment
  • Exhibit 03: Types of pain scales
  • Exhibit 04: Treatment options for pain
  • Exhibit 05: Commonly used non-opioids for pain management
  • Exhibit 06: Commonly used adjuvant medicines for pain
  • Exhibit 07: Pain management
  • Exhibit 08: Pipeline portfolio: Major drug candidates under development for pain management
  • Exhibit 09: Global pain management drugs market 2015-2020 ($ billions)
  • Exhibit 10: Five forces analysis
  • Exhibit 11: Global pain management drugs market by drug class
  • Exhibit 12: Segmentation of global pain management drugs market by drug class, 2015
  • Exhibit 13: Global opioids market 2015-2020 ($ billions)
  • Exhibit 14: Key drivers and challenges of global opioids market
  • Exhibit 15: Global NSAIDs market 2015-2020 ($ billions)
  • Exhibit 16: Key drivers and challenges of global NSAIDs market
  • Exhibit 17: Global pain management drugs market segmentation by type
  • Exhibit 18: Global pain management drugs market segmentation 2015
  • Exhibit 19: Global musculoskeletal pain drugs market 2015-2020 ($ billions)
  • Exhibit 20: Global surgical and trauma drugs market 2015-2020 ($ billions)
  • Exhibit 21: Global cancer pain drugs market 2015-2020 ($ billions)
  • Exhibit 22: Global neuropathic pain drugs market 2015-2020 ($ billions)
  • Exhibit 23: Global migraine pain drugs market 2015-2020 ($ billions)
  • Exhibit 24: Global obstetrical pain drugs market 2015-2020 ($ billions)
  • Exhibit 25: Global fibromyalgia pain drugs market 2015-2020 ($ billions)
  • Exhibit 26: Global burn pain drugs market 2015-2020 ($ billions)
  • Exhibit 27: Global dental/facial pain drugs market 2015-2020 ($ billions)
  • Exhibit 28: Global pediatric pain drugs market 2015-2020 ($ billions)
  • Exhibit 29: Global pain management drugs market by type: YoY revenue and growth 2015-2020
  • Exhibit 30: Global pain management drugs market by geographical segmentation 2015
  • Exhibit 31: Global pain management drugs market revenue by geography 2015-2020 ($ billions)
  • Exhibit 32: Pain management drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 33: Pain management drugs market in EMEA 2015-2020 ($ billions)
  • Exhibit 34: Pain management drugs market in APAC 2015-2020 ($ billions)
  • Exhibit 35: Global pain management drugs market: YoY revenue and growth based on geography 2015-2020
  • Exhibit 36: Impact of drivers
  • Exhibit 37: Challenges in global pain management drugs market
  • Exhibit 38: Impact of drivers and challenges
  • Exhibit 39: Trends in global pain management drugs market
  • Exhibit 40: AstraZeneca: Key pain products segmentation by revenue 2014
  • Exhibit 41: AstraZeneca: YoY growth rate and revenue of Vimovo 2012-2014 ($ millions)
  • Exhibit 42: AstraZeneca: Key takeaways
  • Exhibit 43: Endo International: YoY growth rate and revenue of Opana ER 2012-2014 ($ millions)
  • Exhibit 44: Endo International: YoY growth rate and revenue of Voltaren 2012-2014 ($ millions)
  • Exhibit 45: Endo International: YoY growth rate and revenue of Lidoderm 2012-2014 ($ millions)
  • Exhibit 46: Endo International: YoY growth rate and revenue of Percocet 2012-2014 ($ millions)
  • Exhibit 47: Endo International: Key takeaways
  • Exhibit 48: Johnson & Johnson: Key takeaways
  • Exhibit 49: Pfizer: YoY growth rate and revenue of Lyrica 2012-2014 ($ billions)
  • Exhibit 50: Pfizer: YoY growth rate and revenue of Celebrex 2012-2014 ($ billions)
  • Exhibit 51: YoY growth rate and revenue of Relpax 2012-2014 ($ millions)
  • Exhibit 52: Pfizer: Key takeaways
  • Exhibit 53: Purdue Pharma: Key takeaways
Back to Top